Retail entity
Every one of those 1 sits in a single category, earnings. Blue Buffalo is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Blue Buffalo is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Retail story that mention Protalix BioTherapeutics, all published on March 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Retail stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protalix BioTherapeutics. Shared-story counts are live from our verified record — not editorial picks.
General Mills reported disappointing results for the recent quarter, missing both revenue and earnings estimates as the consumer packaged goods sector faces persistent volume pressure. Despite the shortfall, the company reaffirmed its fiscal 2026 guidance, signaling confidence in a recovery driven by brand investment and supply chain efficiencies.
Protalix BioTherapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
